cupure logo
Fresenius Completes Acquisition of Biopharma Subsidiary mAbxience for Up to €750 Million
Stern

Fresenius Completes Acquisition of Biopharma Subsidiary mAbxience for Up to €750 Million

Fresenius has fully acquired its biopharma subsidiary mAbxience for up to €750 million, enhancing its business portfolio. A condition applies to €50 million of the deal.

Comments

Read this story in other languages

Similar News from External Sources

How we write our stories →

DOWNLOAD OUR APP

Cupure iOS App

Cupure writes the day's most important stories in seven languages. The name comes from the French 'coupure de journal' — a newspaper clipping — our promise of concise, relevant news.

For advertising inquiries, content suggestions, or to flag a concern about a news item or content, you can reach us. We value your feedback. Contact form